CL2017003373A1 - Métodos de modulación de moléculas de vigilancia de adn citosólicas. - Google Patents

Métodos de modulación de moléculas de vigilancia de adn citosólicas.

Info

Publication number
CL2017003373A1
CL2017003373A1 CL2017003373A CL2017003373A CL2017003373A1 CL 2017003373 A1 CL2017003373 A1 CL 2017003373A1 CL 2017003373 A CL2017003373 A CL 2017003373A CL 2017003373 A CL2017003373 A CL 2017003373A CL 2017003373 A1 CL2017003373 A1 CL 2017003373A1
Authority
CL
Chile
Prior art keywords
modulation methods
molecules
cytosolic dna
dna monitoring
monitoring molecules
Prior art date
Application number
CL2017003373A
Other languages
English (en)
Inventor
Thomas Ilg
Albert Abraham
Jason Nickell
Daniel Keil
Christian Weiss
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of CL2017003373A1 publication Critical patent/CL2017003373A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

<p>MÉTODOS PARA GENERAR UNA RESPUESTA INMUNOLÓGICA EN UN SUJETO MEDIANTE LA ACTIVACIÓN DE MOLÉCULAS Y VÍAS DE SEÑALIZACIÓN DE INMUNIDAD INNATA ESPECÍFICAS. EN PARTICULAR, SE USA UNA COMPOSICIÓN INMUNOMODULADORA PARA ESTIMULAR MOLÉCULAS Y VÍAS DE SEÑALIZACIÓN DE INMUNIDAD INNATA.</p>
CL2017003373A 2015-06-26 2017-12-26 Métodos de modulación de moléculas de vigilancia de adn citosólicas. CL2017003373A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562185230P 2015-06-26 2015-06-26

Publications (1)

Publication Number Publication Date
CL2017003373A1 true CL2017003373A1 (es) 2018-06-29

Family

ID=56235815

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003373A CL2017003373A1 (es) 2015-06-26 2017-12-26 Métodos de modulación de moléculas de vigilancia de adn citosólicas.

Country Status (22)

Country Link
US (1) US20190233825A1 (es)
EP (1) EP3313376A2 (es)
JP (1) JP2018518511A (es)
KR (1) KR20180021874A (es)
CN (1) CN108472255A (es)
AR (1) AR105160A1 (es)
AU (1) AU2016282879A1 (es)
BR (1) BR112017028121A2 (es)
CA (1) CA2990526A1 (es)
CL (1) CL2017003373A1 (es)
CR (1) CR20180003A (es)
DO (1) DOP2017000313A (es)
HK (1) HK1256128A1 (es)
IL (1) IL256264A (es)
MX (1) MX2017017141A (es)
PE (1) PE20181208A1 (es)
PH (1) PH12017502413A1 (es)
RU (1) RU2018102915A (es)
SG (1) SG10201913395VA (es)
TW (1) TW201710509A (es)
UY (1) UY36756A (es)
WO (1) WO2016207314A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015349680A1 (en) 2014-11-21 2017-06-08 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
CA3031778A1 (en) 2016-07-26 2018-02-01 Bayer Animal Health Gmbh Increased fertility in bovine species
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US155950A (en) * 1874-10-13 Improvement in hand-saws
DK0772619T4 (da) * 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US6339068B1 (en) * 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
WO2002024899A2 (en) * 2000-09-25 2002-03-28 Valentis, Inc. Improved system for regulation of transgene expression
AU2002953015A0 (en) * 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
WO2005033265A2 (en) * 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
AR044437A1 (es) * 2003-05-29 2005-09-14 Schering Plough Ltd Composiciones y metodo para el tratamiento de infecciones en ganado vacuno y porcino
WO2006017857A2 (en) * 2004-08-13 2006-02-16 The Trustees Of The University Of Pennsylvania Antibiotic resistance free dna vaccines
JP5530065B2 (ja) * 2004-08-13 2014-06-25 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗生物質耐性欠失ワクチンの作成方法
SI2992899T1 (sl) * 2009-05-14 2020-10-30 Bayer Intellectual Property Gmbh Povečan imunski odziv pri ptičjih vrstah
NZ612285A (en) * 2010-12-22 2015-09-25 Bayer Ip Gmbh Enhanced immune response in bovine species
MX346596B (es) * 2011-05-26 2017-03-23 Intervet Int Bv Oligodesoxinucleotidos inmunoestimuladores.
AR091569A1 (es) * 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
MX2016010993A (es) * 2014-02-28 2017-05-01 Bayer Animal Health Gmbh Plasmidos inmunoestimuladores.

Also Published As

Publication number Publication date
IL256264A (en) 2018-02-28
MX2017017141A (es) 2018-03-09
UY36756A (es) 2017-01-31
EP3313376A2 (en) 2018-05-02
SG10201913395VA (en) 2020-03-30
PH12017502413A1 (en) 2018-06-25
CR20180003A (es) 2018-03-20
BR112017028121A2 (pt) 2018-09-04
RU2018102915A3 (es) 2019-12-05
WO2016207314A2 (en) 2016-12-29
HK1256128A1 (zh) 2019-09-13
KR20180021874A (ko) 2018-03-05
AU2016282879A1 (en) 2018-01-18
JP2018518511A (ja) 2018-07-12
CN108472255A (zh) 2018-08-31
RU2018102915A (ru) 2019-07-29
US20190233825A1 (en) 2019-08-01
AR105160A1 (es) 2017-09-13
DOP2017000313A (es) 2018-02-28
CA2990526A1 (en) 2016-12-29
PE20181208A1 (es) 2018-07-23
TW201710509A (zh) 2017-03-16
WO2016207314A3 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
CY1124845T1 (el) Μεθοδοι παροχης μονοκλωνου rna
CY1123642T1 (el) Αντισωματα enanti-pd-1
CY1124096T1 (el) Αντισωματα τα οποια στοχευουν αντιγονο ωριμανσης β-κυτταρων και μεθοδοι χρησης
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
CO2017004386A2 (es) Fluidos de estimulación de lgn de grado y
CL2017002820A1 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
CL2017003373A1 (es) Métodos de modulación de moléculas de vigilancia de adn citosólicas.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
AR103225A1 (es) Composiciones detergentes, variantes de lipasa y polinucleótidos que las codifican
CL2016001716A1 (es) Anticuerpo moléculas de tim-3 y usos de los mismos
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
CY1118168T1 (el) Διπλα ειδικα αντισωματα εναντι cd3εψιλον και bcma
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
UY37523A (es) Anticuerpos anti-ox40 y sus usos
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
AR097421A1 (es) Método de canalización in situ y sistema para aumentar la conductividad de la fractura
EA201691945A1 (ru) Антитела к гемагглютинину вируса гриппа типа b и способы их применения
CL2017002881A1 (es) Anticuerpos anti-fcrn
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
PE20220297A1 (es) Neutralizacion del virus chikungunya mediada por anticuerpos
CY1125033T1 (el) Σκευασμα μεθοτρεξατης